Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ablynx: Balancing Partners And Pipeline

Executive Summary

Next-generation antibody company Ablynx boasts a series of technology partnership deals but its primary goal is to develop drugs. Can partners’ money fund a pipeline with sufficient focus to be manageable, but enough breadth to survive?

You may also be interested in...

BioInvent To Cut Jobs By A Quarter Following Head-To-Head Clinical Trial Disappointment

Sweden's antibody platform company BioInvent moves quickly to reorganize following disappointing Phase IIb clinical results with a potential antithrombotic antibody.

Post-Pfizer Deal Setback, Ablynx Finds Data Differentiating Its Nanobody Ozoralizumab From Other Anti-TNFs

Ablynx releases Phase II open-label extension clinical data showing its lead nanobody, ozoralizumab, allows individualized dosing in rheumatoid arthritis and doesn't induce neutralizing antibodies that affect efficacy, potentially differentiating it from marketed TNF inhibitors.

Amgen’s Stealth Enbrel Patent May Block Biosimilars; Scenario May Apply To Other Biologics

Amgen’s patent may keep Enbrel biosimilars off the market until at least 2028. Other biosimilar sponsors could face similar submarine patents that derail their commercialization plans.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts